| Drug Name |
Belatacept |
| Drug ID |
BADD_D00223 |
| Description |
Belatacept is a soluble fusion protein, which links the extracellular domain of human cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) to the modified Fc (hinge, CH2, and CH3 domains) portion of human immunoglobulin G1 (IgG1). Structurally, abatacept is a glycosylated fusion protein with a MALDI-MS molecular weight of 92,300 Da and it is a homodimer of two homologous polypeptide chains of 357 amino acids each. It is produced through recombinant DNA technology in mammalian CHO cells. The drug has activity as a selective co-stimulation modulator with inhibitory activity on T lymphocytes. It is approved for the treatment of rheumatoid arthritis. Belatacept selectively blocks the process of T-cell activation. It was developed by Bristol-Myers-Squibb. Belatacept is only 2 amino acids different from abatacept (Orencia). FDA approved on June 15, 2011. |
| Indications and Usage |
For prophylaxis of organ rejection. It is also used concomitantly with basiliximumab for induction therapy, mycophenolate, and corticosteriods in kidney transplant recepients that are seropositive for the Epstein-Barr virus. |
| Marketing Status |
approved; investigational |
| ATC Code |
L04AA28 |
| DrugBank ID |
DB06681
|
| KEGG ID |
D03222
|
| MeSH ID |
D000069594
|
| PubChem ID |
Not Available
|
| TTD Drug ID |
D0N4HB
|
| NDC Product Code |
83157-0371; 0952-0371; 0003-0371 |
| UNII |
E3B2GI648A
|
| Synonyms |
Abatacept | CTLA-4-Ig | Cytotoxic T Lymphocyte-Associated Antigen 4-Immunoglobulin | Cytotoxic T Lymphocyte Associated Antigen 4 Immunoglobulin | CTLA4-Ig | CTLA4-Ig Immunoconjugate | CTLA4 Ig Immunoconjugate | Immunoconjugate, CTLA4-Ig | CTLA4-Fc | BMS224818 | BMS-224818 | BMS 224818 | Belatacept | Orencia | BMS 188667 | BMS-188667 | BMS188667 | LEA29Y | Nulojix |
